Biohaven Pharma (BHVN) Tops Q3 EPS by 49c; Reports Cash and Cash Equivalents of $523.9M

Biohaven Pharma (NYSE: BHVN) reported Q3 EPS of ($1.91), $0.49 better than the analyst estimate of ($2.40). Revenue for the quarter came in at $135.7 million versus the consensus estimate of $128.4 million.

For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.

You May Also Be Interested In

• BofA Securities Downgrades Biohaven Pharma (BHVN) to Underperform
• Lockheed Martin frontrunner for $3.5B Ultra Maritime deal, sources say - FT
• Bending Spoons closes IPO, raises ~$954M on Nasdaq